Our data therefore provide important confirmatory evidence of the proportion of low grade disease positive for HPV types 6, 11, 16, or 18 (37% (366/984) of cervical intraepithelial neoplasia grade I, 87% (305/351) of condyloma (tables 3 and 5, intention to treat placebo groups)).
We also sought to describe the proportion of the low grade disease burden that can be prevented by vaccination against HPV types 6, 11, 16, and 18.
We observed in the R02 trial a higher proportion of lobular and low grade carcinoma in excluded cases.
In both cases, we observed that the proportions of lobular and low grade carcinoma were significantly higher in excluded material (Additional file 3 and 4).
Furthermore, our data indicate that a large proportion of cell divisions in low grade Urobasal tumors are associated with the basal membrane, possibly giving rise to asymmetrical divisions.
Between 2002 and 2004, there was a slightly higher proportion of low-grade tumours, but between 2005 and 2007, there was a lower proportion of them.
For grade, incidence screens yielded the highest proportion of grade I and a low grade III, whereas interval cancers showed the converse, with low grade I and high grade III proportions.
A high proportion of breast tumours with a low grade of malignancy in this series of operable breast cancer patients may explain discrepancies concerning the prognostic value of amplification and of overexpression of cyclin D1.
However, a significant proportion of low-grade cervical intraepithelial neoplasia cases showed aberrant staining patterns with 52% staining negative and 9% staining strongly positive.
LR-HPV types are purported to cause a substantial proportion of low-grade and borderline findings on cytology.
